Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524871 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
A Phase 1 study of Advanced Liver Cancers, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT04524871 is a Phase 1 study of Advanced Liver Cancers that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 518 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT04524871, a Phase 1 study of Advanced Liver Cancers, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tocilizumab
- DRUG Bevacizumab 15 mg/kg
- DRUG Tiragolumab
- DRUG TPST-1120
Study Locations (20)
California
- UC Irvine Medical Center - Costa Mesa
- City of Hope - Duarte
- UC Irvine Medical Center - Orange
- University of California San Diego Medical Center - San Diego
- University of California San Francisco Cancer Center - San Francisco
- UCLA Center for East - Santa Monica
Other
- Beijing Cancer Hospital - Beijing
- Zhongshan Hospital Fudan University - Shanghai
- Centre Georges Francois Leclerc - Dijon
- CHU Hôpitaux de Marseille - Marseille
Colorado
- Cherry Creek Medical Center - Aurora
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
- UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital - Highlands Ranch
Texas
- Parkland Health & Hospital System - Dallas
- The University of Texas Southwestern Medical Center at Dallas - Dallas
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Kentucky
- University of Kentucky - Markey Cancer Center - Lexington
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524871
The ClinicalTrials.gov registry entry for NCT04524871 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Liver Cancers appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04524871 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT04524871 about?
NCT04524871 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)". This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or...
What is the current status of trial NCT04524871?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2020-11-01. Estimated completion is 2027-12-31.
What conditions does trial NCT04524871 study?
This clinical trial studies the following conditions: Advanced Liver Cancers.
What interventions are being tested in trial NCT04524871?
The interventions under investigation include: Atezolizumab (DRUG), Tocilizumab (DRUG), Bevacizumab 15 mg/kg (DRUG), Tiragolumab (DRUG), TPST-1120 (DRUG).
Who is sponsoring clinical trial NCT04524871?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04524871 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.